Software and scientific consulting services provider Certara has signed a research agreement with The Hamner Institutes for Health Sciences, to explore the scientific benefits of using its Simcyp Simulator to drive hepatic drug exposure within the latter's drug-induced liver injury (DILI) model.
As part of the agreement, The Hamner's DILIsym modeling software will first be integrated into Certara's Simcyp population-based simulator.
The integrated product's simulation capabilities will later be tested with respect to drug exposure and resultant liver toxicity.
Certara R&D vice president Dr Amin Rostami said that the company is developing a systems- and population-based approach to help with early pre-clinical assessment of drug toxicity risk.
"Our Simcyp Simulator can already model the population variability in pharmacokinetic and pharmacodynamic responses and cardiotoxicity scenarios," Dr Rostami added.
"We are looking forward to partnering with The Hamner scientists to extend our population safety assessment tools to liver toxicity."
Certara, and The Hamner's partnership is part of the initiative led by Dr Paul Watkins, director of The Hamner-University of North Carolina Institute for Drug Safety Sciences.
